Lymphoma

Pre-transplant immune checkpoint inhibitors extended survival for patients with relapsed classic Hodgkin lymphoma compared with chemotherapy, according to results of a retrospective study.

The FDA approved two oncology regimens on Jan. 16.

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those who received the agents in pivotal trials.

SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about results from the REALBiTE study presented at Annual Meeting and Exposition.

Stage at diagnosis and survival among younger individuals with cancer varied considerably by race, according to a retrospective cohort study.

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections.